P
26.48
10.01 (60.78%)
AIStockmoo Score
-0.3
| Analyst Consensus | 0.0 |
| Insider Activity | 1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.30 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAVIS TODD C | 13.50 | - | 1,500,000 | 20,250,000 |
| FRANCIS KNUETTEL II | 13.50 | - | 10,000 | 135,000 |
| FRIEDBERG EZRA M | 13.50 | - | 80,000 | 1,080,000 |
| LIGAND PHARMACEUTICALS INC | 13.50 | - | 1,500,000 | 20,250,000 |
| Aggregate Net Quantity | 3,090,000 | |||
| Aggregate Net Value ($) | 41,715,000 | |||
| Aggregate Avg. Buy ($) | 13.50 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC | 01 Jul 2025 | Acquired (+) | 1,500,000 | 13.50 | 20,250,000 | |
| DAVIS TODD C | Director | 01 Jul 2025 | Acquired (+) | 1,500,000 | 13.50 | 20,250,000 |
| FRANCIS KNUETTEL II | Officer | 01 Jul 2025 | Acquired (+) | 10,000 | 13.50 | 135,000 |
| FRIEDBERG EZRA M | Director | 01 Jul 2025 | Acquired (+) | 80,000 | 13.50 | 1,080,000 |
| Date | Type | Details |
|---|---|---|
| 10 Jul 2025 | Announcement | Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |